Lown Right Care
Reducing Overuse and Underuse

Benefits and Risks of Testosterone Replacement Therapy in Men

Andy Lazris, MD
Alan R. Roth, DO

American Family Physician. 2026;114(3):296-298.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

CASE SCENARIO

A 72-year-old man presents for follow-up for hypertension and hyperlipidemia, for which he takes atorvastatin, metoprolol, and amlodipine. His body mass index is 28 kg/m2, and he has no history of cardiovascular disease. He is sedentary and admits to eating too much junk food. He report daily fatigue with some subjective muscle weakness, decreased libido, and erectile dysfunction. He has read on the internet that testosterone is often low at his age and that replacing it could improve his symptoms.

CLINICAL COMMENTARY

Testosterone levels tend to diminish with age, declining by 2.8% each year after age 40 years. Approximately 20% of men in their 60s and 50% of men in their 80s have testosterone levels below 300 ng/dL (10.41 nmol/L), which is considered testosterone deficiency.1,2 Older men are more likely to experience sexual dysfunction, muscle mass loss, fatigue, and low bone density, all linked to decreased testosterone.3 Although 50% of men older than 65 years report symptoms of sexual dysfunction, it is unclear how many of them have low testosterone levels and whether low testosterone is the sole cause of their symptoms.4

In one study, approximately 5% of men in their 70s experience sexual symptoms concomitant with low testosterone levels.5 Still, many men use exogenous testosterone to relieve symptoms and increase muscle mass. Between 2000 and 2013, testosterone supplement sales in the United States increased from $100 million to $2.7 billion, and sales are estimated to increase to $4.3 billion by 2030.5,6

Testosterone measurement and replacement therapy are controversial. Most studies suggest that multiple morning testosterone measurements (before 10 am) are needed to accurately diagnose male hypogonadism because levels are diurnal, with known decline from morning into afternoon.7 One study found that two-thirds of physicians measure levels in the afternoon, and those artificially low levels account for approximately 70% of low levels recorded, resulting in a high false-positive rate.8

Most studies used a morning cut-off level of 300 ng/dL as a threshold for hypogonadism after multiple morning measurements, although norms differ with age.9 In addition, many formulations of testosterone replacement therapy are available (eg, pills, patches, gels, injections), none of which is clearly superior.3 A meta-analysis that found benefit from testosterone replacement therapy overall found no difference among different formulations.10 Most studies in this analysis used only one form of testosterone replacement therapy, typically a patch.

Benefits

It is important to distinguish between studies that enrolled men receiving testosterone for sexual symptoms regardless of their testosterone level from those that enrolled only men with documented low morning testosterone levels. A recent Cochrane review of 43 randomized controlled trials including men with sexual dysfunction who took testosterone regardless of testosterone levels found no benefit. Most of the funded studies (19 of 21) were supported by pharmaceutical companies, and many excluded men with underlying medical and psychological illness. Study duration ranged from 6 weeks to 24 months.11,12

The most consistent benefit of testosterone replacement therapy in men with low levels is improved sexual desire and function. A small trial in China showed significant improvement in erectile dysfunction with treatment vs placebo after 3 months; the International Index of Erectile Function-15 score (range 0–30) increased by 14.4 in the treatment group and decreased by 5.2 in the placebo group.13 The Testosterone Trials, a group of seven randomized trials that evaluated the effects of testosterone treatment in 790 older men with low testosterone over 1 year, showed statistically significant improvements in sexual function and desire among treated men, with higher levels of testosterone correlating with improved sexual function.14

ANDY LAZRIS, MD, CMD, is the medical director at Personal Physician Care, Columbia, Maryland.

ALAN R. ROTH, DO, FAAFP, FAAHPM, is the chairman of the Department of Family Medicine, Ambulatory Care and Community Medicine, and chief of the Department of Integrative Pain and Palliative Care Medicine, MediSys Health Network, Jamaica Hospital Medical Center, Jamaica, New York.

Address correspondence to Andy Lazris, MD, CMD, at alazris50@gmail.com.

Author Disclosure: No relevant financial relationships.

  1. 1.Institute of Medicine. Testosterone and Aging: Clinical Research Directions. National Academies Press; 2004.
  2. 2.Abdel-Sater KA. The role of anti-aging approaches in managing hypogonadism in sedentary older males. Front Aging. 2024;13(5):1514438.
  3. 3.Bassil N, et al. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5(3):427-448.
  4. 4.Mark KP, et al. Erectile dysfunction prevalence in the United States: report from the 2021 National Survey of Sexual Wellbeing. J Sex Med. 2024;21(4):296-303.
  5. 5.Bhasin S. Testosterone replacement in aging men: an evidence-based patient-centric perspective. J Clin Invest. 2021;131(4):e146607.
  6. 6.Strategic Market Research. Testosterone replacement therapy (TRT) market report 2030. October 2025. Accessed March 8, 2026. https://www.strategicmarketresearch.com/market-report/testosterone-replacement-therapy-market
  7. 7.Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
  8. 8.Windham AK, et al. Association between daily sample collection time and results of testosterone testing in adult males. Am J Clin Pathol. 2022;158:S124.
  9. 9.Heidelbaugh JJ, et al. Testosterone replacement therapy for male hypogonadism. Am Fam Physician. 2024;109(6):543-549.
  10. 10.Elliott J, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017;7(11):e015284.
  11. 11.Lee H, et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024(1):CD013071.
  12. 12.Touchet BJ, et al. Testosterone replacement in men with sexual dysfunction in the absence of hypogonadism. Am Fam Physician. 2025;111(4):311-312.
  13. 13.Chiang HS, et al. Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology. 2009;73(4):762-766.
  14. 14.Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.
  15. 15.Emmelot-Vonk MH, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39-52.
  16. 16.Resnick SM, et al. Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. JAMA. 2017;317(7):717-727.
  17. 17.Orengo CA, et al. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18(1):20-24.
  18. 18.Cheetham TC, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177(4):491-499.
  19. 19.Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117.
  20. 20.Bhasin S, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6(12):e2348692.
  21. 21.D'Andrea S, et al. Endogenous transient doping: physical exercise acutely increases testosterone levels—results from a meta-analysis. J Endocrinol Invest. 2020;43(10):1349-1371.
  22. 22.Healy R, et al. The effects of aerobic exercise training on testosterone concentration in individuals who are obese or have type 2 diabetes: a systematic review and meta-analysis. Sports Med Open. 2024;10(1):117.
  23. 23.Whittaker J, et al. Low-fat diets and testosterone in men: systematic review and meta-analysis of intervention studies. J Steroid Biochem Mol Biol. 2021;210:105878.

Lown Institute Right Care Alliance is a grassroots coalition of clinicians, patients, and community members organizing to make health care institutions accountable to communities and to put patients, not profits, at the heart of health care.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

A collection of Lown Right Care published in AFP is available at https://www.aafp.org/afp/rightcare.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.